Physician profile
Caroline Kim
NPI 1376123752
$1,584.63
in general payments reported to CMS, 2019-2025
18 companies · $1,525 in 2025
The $1,525 reported for 2025 was more than what 92% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $59.39 · 2025: $1,525.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,585.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,584.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $255.08 | 2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $209.42 | 2025 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $195.78 | 2025 | Airsupra, Breztri, Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $122.06 | 2024-2025 | Jardiance |
| Exact Sciences Corporation | $115.11 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Neurocrine Biosciences, INC. | $103.76 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $89.57 | 2025 | Camzyos, Eliquis |
| Phathom Pharmaceuticals, INC. | $76.13 | 2025 | Voquezna |
| Astellas Pharma US INC | $68.12 | 2025 | Veozah |
| Amgen INC. | $68.10 | 2025 | Otezla, Repatha, Evenity |
| Heartflow, INC. | $67.00 | 2025 | |
| Abbvie INC. | $65.33 | 2025 | |
| Corcept Therapeutics | $43.46 | 2025 | Korlym |
| Glaxosmithkline, LLC. | $28.70 | 2025 | Shingrix, Arexvy |
| Almatica Pharma LLC | $21.41 | 2025 | Loreev Xr |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $20.54 | 2025 | Capvaxive, Gardasil 9 |
| Radius Health, INC. | $20.53 | 2025 | Tymlos |
| Kowa Pharmaceuticals America, INC. | $14.53 | 2025 | Zoryve |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Caroline Kim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.